Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
69639-0120-01 69639-0120 Mechlorethamine hydrochloride VALCHLOR 0.012 g/60g Chemotherapy Alkylating Agent Nitrogen Mustard TOPICAL Nov. 8, 2018 In Use
70121-1631-01 70121-1631 Thiotepa Tepadina 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Aug. 15, 2017 In Use
70518-2711-00 70518-2711 Methotrexate Sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral April 27, 2020 In Use
71288-0108-06 71288-0108 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous June 26, 2020 In Use
75834-0190-01 75834-0190 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 17, 2020 In Use
75840-0111-00 75840-0111 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Oct. 1, 2012 In Use
75840-0111-01 75840-0111 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Oct. 1, 2012 In Use
00054-0482-13 00054-0482 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 7, 2021 In Use
00093-7290-01 00093-7290 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral March 28, 2014 In Use
00093-7290-56 00093-7290 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral March 28, 2014 In Use
00409-3414-01 00409-3414 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Feb. 2, 2006 In Use
00409-4759-01 00409-4759 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 7, 2006 In Use
00003-2328-22 00003-2328 Ipilimumab Yervoy 5.0 mg/mL Immunotherapy Checkpoint Inhibitor CTLA-4 Intravenous March 25, 2011 In Use
00006-3941-01 00006-3941 Fosaprepitant Dimeglumine Emend 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 19, 2010 In Use
00006-3941-32 00006-3941 Fosaprepitant Dimeglumine Emend 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 12, 2010 In Use
00009-0626-01 00009-0626 Medroxyprogesterone Acetate Depo-Provera 400.0 mg/mL Hormonal Therapy Progestin Intramuscular Nov. 1, 1960 In Use
65483-0116-07 65483-0116 Aldesleukin Proleukin 1.1 mg/mL Immunotherapy Cytokine Interleukin-2 Intravenous May 5, 1992 In Use
45802-0368-53 45802-0368 Imiquimod Imiquimod 12.5 mg/.25g Immunotherapy Immunomodulator Dermatological Agent Topical July 12, 2012 In Use
45802-0368-62 45802-0368 Imiquimod Imiquimod 12.5 mg/.25g Immunotherapy Immunomodulator Dermatological Agent Topical Nov. 9, 2010 In Use
50242-0070-01 50242-0070 Obinutuzumab Gazyva 1000.0 mg/40mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov. 1, 2013 In Use
50242-0070-86 50242-0070 Obinutuzumab Gazyva 1000.0 mg/40mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov. 4, 2013 In Use
51144-0020-01 51144-0020 ENFORTUMAB VEDOTIN PADCEV 20.0 mg/2mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec. 18, 2019 In Use
51144-0030-01 51144-0030 ENFORTUMAB VEDOTIN PADCEV 30.0 mg/3mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec. 18, 2019 In Use
59572-0402-00 59572-0402 Lenalidomide Revlimid 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral May 9, 2012 In Use
59572-0402-28 59572-0402 Lenalidomide Revlimid 2.5 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral May 9, 2012 In Use
59572-0405-00 59572-0405 Lenalidomide Revlimid 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Dec. 27, 2005 In Use
59572-0405-28 59572-0405 Lenalidomide Revlimid 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral March 3, 2009 In Use
59572-0410-00 59572-0410 Lenalidomide Revlimid 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Dec. 27, 2005 In Use
59572-0410-28 59572-0410 Lenalidomide Revlimid 10.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral March 3, 2009 In Use
59572-0415-00 59572-0415 Lenalidomide Revlimid 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral July 7, 2006 In Use
59572-0415-21 59572-0415 Lenalidomide Revlimid 15.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral July 7, 2006 In Use
59572-0420-00 59572-0420 Lenalidomide Revlimid 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral June 10, 2013 In Use
59572-0420-21 59572-0420 Lenalidomide Revlimid 20.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral June 10, 2013 In Use
59572-0425-00 59572-0425 Lenalidomide Revlimid 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral July 7, 2006 In Use
59572-0425-21 59572-0425 Lenalidomide Revlimid 25.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral March 3, 2009 In Use
63459-0103-10 63459-0103 Rituximab-abbs Truxima 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous May 4, 2020 In Use
63459-0104-50 63459-0104 Rituximab-abbs Truxima 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous May 4, 2020 In Use
63459-0305-47 63459-0305 TRASTUZUMAB HERZUMA Immunotherapy Monoclonal Antibody HER2 March 16, 2020 In Use
00078-0672-01 00078-0672 Topotecan Hydrochloride Hycamtin 0.25 mg/1 Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Oral July 7, 2017 In Use
00078-0673-01 00078-0673 Topotecan Hydrochloride Hycamtin 1.0 mg/1 Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Oral Feb. 24, 2017 In Use
00078-0674-61 00078-0674 Topotecan Hydrochloride Hycamtin 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 21, 2016 In Use
00143-9701-01 00143-9701 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 20, 2010 In Use
00143-9702-01 00143-9702 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 20, 2010 In Use
00378-4791-06 00378-4791 Fluorouracil Fluorouracil 5.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical Sept. 19, 2013 In Use
00378-7096-01 00378-7096 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral July 1, 2013 In Use
00378-7096-93 00378-7096 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral June 17, 2013 In Use
00409-0186-01 00409-0186 Gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 26, 2011 In Use
00409-0368-01 00409-0368 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 9, 2018 In Use
00597-0141-30 00597-0141 Afatinib Gilotrif 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug. 13, 2013 In Use
00703-3678-01 00703-3678 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Aug. 1, 2012 In Use
00703-3678-81 00703-3678 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Dec. 14, 2015 In Use
15054-0043-01 15054-0043 Irinotecan Hydrochloride Onivyde 4.3 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Oct. 22, 2015 In Use
16714-0027-01 16714-0027 Irinotecan hydrochloride Irinotecan hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 15, 2020 In Use
16714-0131-01 16714-0131 Irinotecan hydrochloride Irinotecan hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 15, 2020 In Use
16729-0072-12 16729-0072 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral June 9, 2015 In Use
16729-0073-29 16729-0073 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral May 20, 2015 In Use
16729-0114-08 16729-0114 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous March 3, 2015 In Use
16729-0114-11 16729-0114 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous March 3, 2015 In Use
16729-0114-31 16729-0114 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous March 22, 2015 In Use
16729-0114-32 16729-0114 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Jan. 1, 2020 In Use
16729-0151-31 16729-0151 Topotecan Hydrochloride topotecan hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous July 23, 2013 In Use
16729-0267-63 16729-0267 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 22, 2013 In Use
16729-0267-64 16729-0267 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 2, 2013 In Use
16729-0267-65 16729-0267 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous May 30, 2013 In Use
16729-0277-03 16729-0277 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous March 7, 2014 In Use
16729-0277-30 16729-0277 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous March 7, 2014 In Use
16729-0277-35 16729-0277 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous March 7, 2014 In Use
24338-0050-08 24338-0050 Carmustine Gliadel 7.7 mg/1 Chemotherapy Alkylating Agent Nitrosourea Intracavitary Dec. 13, 2012 In Use
25021-0204-01 25021-0204 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 15, 2014 In Use
25021-0204-05 25021-0204 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 15, 2014 In Use
25021-0230-02 25021-0230 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Aug. 15, 2014 In Use
25021-0230-05 25021-0230 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Aug. 15, 2014 In Use
25021-0246-02 25021-0246 Thiotepa Thiotepa 15.0 mg/1.5mL Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical June 15, 2018 In Use
42367-0521-25 42367-0521 Bendamustine Hydrochloride BELRAPZO 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 3, 2019 In Use
43598-0259-40 43598-0259 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 10, 2014 In Use
43598-0348-37 43598-0348 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 11, 2013 In Use
43598-0427-37 43598-0427 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 5, 2014 In Use
45963-0607-55 45963-0607 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous March 1, 2015 In Use
45963-0607-56 45963-0607 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous March 1, 2015 In Use
45963-0615-56 45963-0615 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Jan. 5, 2015 In Use
50742-0401-02 50742-0401 Irinotecan Hydrochloride Irinotecan Hydrochloride 40.0 mg/2mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 5, 2017 In Use
50742-0402-05 50742-0402 Irinotecan Hydrochloride Irinotecan Hydrochloride 100.0 mg/5mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 5, 2017 In Use
50742-0519-02 50742-0519 cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 30, 2020 In Use
50742-0520-05 50742-0520 cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 30, 2020 In Use
50881-0010-01 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov. 16, 2011 In Use
50881-0010-60 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov. 16, 2011 In Use
51285-0366-01 51285-0366 Methotrexate Trexall 5.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51285-0367-01 51285-0367 Methotrexate Trexall 7.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51285-0368-01 51285-0368 Methotrexate Trexall 10.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51285-0369-01 51285-0369 Methotrexate Trexall 15.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51672-4118-02 51672-4118 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical March 17, 2017 In Use
51672-4118-05 51672-4118 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical March 17, 2017 In Use
51672-4118-06 51672-4118 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical March 17, 2017 In Use
50242-0130-01 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Dec. 11, 2015 In Use
50242-0130-86 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Oct. 10, 2017 In Use
54569-1818-09 54569-1818 METHOTREXATE, Methotrexate sodium Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 7, 1953 In Use
54868-5474-00 54868-5474 Erlotinib Hydrochloride Tarceva 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 21, 2005 In Use
55111-0556-10 55111-0556 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 11, 2013 In Use
57962-0070-28 57962-0070 Ibrutinib IMBRUVICA 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Dec. 20, 2017 In Use
57962-0140-09 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use

Found 10,000 results in 5 millisecondsExport these results